Barclays
PTCT icon

Barclays’s PTC Therapeutics PTCT Stock Holding History

Barclays’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,900
Closed -$484K – 5682
2025
Q2 		$484K Buy
+9,900
New +$470K ﹤0.01% 3773
2024
Q4 		– Sell
-21,000
Closed -$779K – 5439
2024
Q3 		$779K Buy
+21,000
New +$703K ﹤0.01% 3516
2019
Q2 		– Sell
-4,400
Closed -$165K – 7197
2019
Q1 		$165K Buy
+4,400
New +$148K ﹤0.01% 4968
2018
Q4 		– Sell
-20,800
Closed -$978K – 7256
2018
Q3 		$978K Sell
20,800
-101,700
-83% -$4.21M ﹤0.01% 3645
2018
Q2 		$4.13M Buy
+122,500
New +$3.82M ﹤0.01% 1884
2018
Q1 		– Sell
-3,400
Closed -$57K – 7270
2017
Q4 		$57K Sell
3,400
-146,300
-98% -$2.48M ﹤0.01% 5672
2017
Q3 		$3M Buy
149,700
+144,900
+3,019% +$2.84M ﹤0.01% 1961
2017
Q2 		$88K Sell
4,800
-32,400
-87% -$437K ﹤0.01% 5004
2017
Q1 		$366K Buy
+37,200
New +$450K ﹤0.01% 3715
2016
Q1 		– Sell
-34,600
Closed -$1.11M – 6379
2015
Q4 		$1.11M Sell
34,600
-1,262,900
-97% -$37.2M ﹤0.01% 2525
2015
Q3 		$33.7M Buy
1,297,500
+1,295,400
+61,686% +$55.4M 0.04% 388
2015
Q2 		$101K Hold
2,100
– – ﹤0.01% 4664
2015
Q1 		$126K Buy
+2,100
New +$128K ﹤0.01% 4693

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Barclays's PTCT Position: Q1 2026 in Review

Barclays reduced its PTC Therapeutics (PTCT) stake by 76% in Q1 2026, selling an estimated $11.8M and leaving 53,079 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

Barclays first reported a position in PTCT in Q3 2013 and has held it in 51 quarters since. The position peaked at $16.7M in Q4 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Barclays held 53,079 shares of PTC Therapeutics worth $3.62M as of Q1 2026.
  • Barclays sold 167,117 PTC Therapeutics shares in Q1 2026, an estimated $11.8M.
  • PTC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2009 holding.
  • Barclays first reported a position in PTC Therapeutics in Q3 2013 and has held it in 51 quarters since.
  • Barclays's PTC Therapeutics position peaked at $16.7M in Q4 2025.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.